Gland Pharma Intrinsic Value
Gland Pharma (GLAND) median intrinsic value is ₹5923.80 from 10 valuation models (range ₹889–₹7405), vs current price ₹2961.90 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. See GLAND P/B ratio history to compare market price against book value per share.
GLAND Valuation Methods Summary — DCF, Graham Number & P/E
Gland Pharma intrinsic value across 10 models vs current price ₹2961.90 — upside/downside and value range per method. For current market price and key ratios, visit Gland Pharma stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1958.88 | ₹1567.10 - ₹2350.66 | -33.9% | EPS: ₹89.04, Sector P/E: 22x |
| Book Value Method | asset | ₹7404.75 | ₹6664.28 - ₹8145.23 | +150.0% | Book Value/Share: ₹6092.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹5923.80 | ₹5331.42 - ₹6516.18 | +100.0% | Revenue/Share: ₹4362.35, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹5923.80 | ₹5331.42 - ₹6516.18 | +100.0% | EBITDA: ₹2500.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹6049.73 | ₹4839.78 - ₹7259.68 | +104.3% | CF Growth: 6.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹888.57 | ₹799.71 - ₹977.43 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1375.67 | ₹1238.10 - ₹1513.24 | -53.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹5923.80 | ₹5331.42 - ₹6516.18 | +100.0% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹3493.79 | ₹3144.41 - ₹3843.17 | +18.0% | EPS: ₹89.04, BVPS: ₹6092.94 |
| Dividend Yield Method | dividend | ₹888.57 | ₹799.71 - ₹977.43 | -70.0% | DPS: ₹20.00, Target Yield: 2.5% |
GLAND Intrinsic Value vs Market Price — All Valuation Models
Gland Pharma fair value range ₹889–₹7405 vs current market price ₹2961.90 across 10 valuation models. Check GLAND market value to track the company's total market size over time.
GLAND Intrinsic Value Analysis — Undervalued or Overvalued?
Gland Pharma median intrinsic value ₹5923.80, current price ₹2961.90 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GLAND?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Gland Pharma (GLAND) is ₹5923.80 (median value). With the current market price of ₹2961.90, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹888.57 to ₹7404.75, indicating ₹888.57 - ₹7404.75.
Is GLAND undervalued or overvalued?
Based on our multi-method analysis, Gland Pharma (GLAND) appears to be trading below calculated value by approximately 100.0%.
GLAND Financial Health — Key Ratios vs Industry Benchmarks
Gland Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.81 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 29.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GLAND Cash Flow Quality — Operating & Free Cash Flow
Gland Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,031 Cr | ₹1,031 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹915 Cr | ₹915 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹997 Cr | ₹123 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹364 Cr | ₹364 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹791 Cr | ₹292 Cr | Positive Free Cash Flow | 7/10 |